Quantcast
Search Daily Dose & Film Annex
Loading

BIO SmartBrief

Daily Dose Newsletter

Monday
Apr092012

Aeolus ($AOLS): BioDefense - Acute Radiation Syndrome. There is Hope !

Aeolus ($AOLS) received a BARDA notice of intent to exercise options is triggered by Aeolus' successful execution of the first year of its contract. (This is positive news for the company).

The bulk of the options are for the period of performance beginning April 1, 2012 and ending March 31, 2013, and include funding for murine and NHP Efficacy studies in Lung Acute Radiation Syndrome (Lung-ARS), GMP manufacturing, and project management costs.

The company expects revenue to increase to $9 to $11M for fiscal year 2012, as a result of the project.

PrintView Printer Friendly Version

EmailEmail Article to Friend

References (3)

References allow you to track sources for this article, as well as articles that were written in response to this article.
  • Response
    Response: index program
    Wonderful Web site, Carry on the great job. Thanks a lot!
  • Response
    Response: Check This Out
    Great Web site, Keep up the fantastic work. Thank you so much!
  • Response
    Daily Dose Equities - Wall Street Analysis for Biomedical Research - Daily Dose Newsroom - Aeolus ($AOLS): BioDefense - Acute Radiation Syndrome. There is Hope !

Reader Comments

There are no comments for this journal entry. To create a new comment, use the form below.

PostPost a New Comment

Enter your information below to add a new comment.

My response is on my own website »
Author Email (optional):
Author URL (optional):
Post:
 
Some HTML allowed: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <code> <em> <i> <strike> <strong>
« DD Education: Which Cell Therapy companies present the best value? Part 2 | Main | Rodman & Renshaw Annual Global Investment Conference September 9-11, 2012 in NYC »